Search fresh public links, source activity, and ready-to-use post angles for Dbv Technologies.
Fresh curated links around DBV Technologies are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
DBV Technologies will submit its Viaskin Peanut FDA application in late 2026 after agreeing to include additional safety data. The post FDA Agreement Clears Regulatory Path for Via...
DBV Technologies has screened the first participant in a pioneering trial of its peanut allergy patch for infants. The post DBV Launches Peanut Patch Study in Infants as Young as S...
Boehringer Ingelheim has landed an exclusive license to Prime Vector Technologies’ viral vector platform for developing next-generation cancer vaccines.
Attovia Therapeutics has filed for an IPO to secure funding for assets, including a potential challenger to Sanofi and Regeneron’s Dupixent and Galderma’s Nemluvio.
The biotech, co-founded by Sofinnova Partners and a former Sanofi immunology R&D head, is testing new biologics against common immune conditions.
U.S.-based Boulevard Bio is paying $20 million upfront to China’s Metis TechBio for the global rights to a trispecific T-cell engager for autoimmune diseases.
The company made the announcement after a new round of research results bolstered the case for the experimental medicine, which may ultimately compete against Dupixent and Ebglyss.
A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.
Novel nanoparticle-based peanut allergy therapy produced encouraging immune responses in Phase 1 and now advances toward larger clinical trials. The post Spanish Biotech Reports En...
ADC Therapeutics Anonymous (not verified) Sun, 06/07/2026 - 17:48 field_thread_url https://cafepharma.com/boards/threads/adc-therapeutics.665008/...
The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Bruk...
Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.
The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.
Ascendant-221 uses a dual-action anti-IgE approach that could offer longer-lasting protection against severe allergic reactions. The post New Biologic Aims to Provide Long-Lasting...
Vega’s lead candidate VGA039 could, if approved, be the first subcutaneous prophylactic therapy with a more convenient once-monthly, self-administered dosing regimen for patients w...
Beigene Anonymous (not verified) Mon, 05/25/2026 - 11:38 field_thread_url https://cafepharma.com/boards/threads/beigene.637588/ board na...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.